Drug Profile
Bamosiran
Alternative Names: SYL-040012Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Sylentis
- Class Antiglaucomas; Small interfering RNA
- Mechanism of Action Beta 2 adrenergic receptor antagonists; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glaucoma; Ocular hypertension
Most Recent Events
- 08 Sep 2021 No development reported - Phase-II for Glaucoma in USA (Ophthalmic) (Sylentis pipeline, September 2021)
- 08 Sep 2021 No development reported - Phase-II for Ocular hypertension in USA (Ophthalmic) (Sylentis pipeline, September 2021)
- 11 Sep 2018 Bamosiran is still in phase II trials for Glaucoma and Ocular hypertension (Sylentis pipeline, September 2018)